Bayer Stock Forecast 2025–2030 | Future Outlook
Bayer is trading against a backdrop of several company-specific developments, including the start of a Phase IIa clinical trial for BAY 3401016 in Alport syndrome (Business Wire, 4 December 2025) and progress in Bayer’s MRI contrast agent programme, where the company is developing the investigational compound gadoquatrane (Financial Times, 3 December 2025).
US legal proceedings related to glyphosate-based products also remain in focus, with recent comments from the Trump administration in support of Bayer’s bid to limit Roundup lawsuits adding to the wider discussion (Reuters, 2 December 2025).
Bayer stock forecast 2026–2030: Analyst price target view
Third-party Bayer price forecasts published in early-December 2025 generally…
